A 35% reduction in the risk of death with apalutamide (Erleada) was seen versus placebo in patients receiving androgen-deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC), according to data from the final analysis of the phase 3 randomized, double-blind, placebo-controlled TITAN trial (NCT02489318).
In the trial, 1052 patients with mCSPC were randomized 1:1 to receive apalutamide plus ADT or placebo plus ADT. Dual primary end points were radiographic progression-free survival (rPFS) and overall survival (OS), according to investigator Kim N. Chi, MD, chief medical officer and vice president of BC Cancer, Vancouver, Canada, who presented the findings at the 2021 Genitourinary Cancers Symposium.
For the TITAN trial (NCT02489318), 1052 patients with mCSPC were randomized 1:1 to receive apalutamide plus ADT or placebo plus ADT. Dual primary end points were…
